Zydus Saroglitazar Mg To Treat Primary Biliary Cholangitis Receives Us Fda Orphan Drug Designation
Zydus, A Leading Discovery Based, Global Pharmaceutical Company, Announced That United States Food And Drug Administration (Fda) Has Granted &Lsquo;Orphan Drug Designation&Rsquo; (Odd) To Saroglitazar Mg For The Treatment Of Patients With Primary Biliary Cholangitis (Pbc).Orphan Drug Designation Provides Eligibility For Certain Development Incentives, Including Tax Credits For Qualified Clinical Testing, Prescription Drug User Fee Exemptions And Seven-Year Marketing Exclusivity Upon Fda Approval. This Follows The Grant Of &Lsquo;Fast Track Designation&Rsquo; By The Us Fda To Saroglitazar Mg For Pbc In December 2020.Saroglitazar Mg Is A Potent And Selective Peroxisome Proliferator-Activated Receptor Alpha And Gamma Dual Agonist. Results Of Phase 2, Prospective Multicentre Randomized Double-Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability And Efficacy Of Saroglitazar Mg In Patients With Primary Biliary Cholangitis (Epics) Was Presented Earlier At The Liver Meeting 2020, The Annual Meeting Of The American Association For The Study Of Liver Diseases (Aasld) [Clinicaltrials.Gov Identifier: Nct03112681].The Treatment Options Are Still Evolving For Pbc And Saroglitazar Holds Immense Potential Based On Its Safety And Efficacy Profile So Far. The Global Market For Pbc Treatment Is Expected To Grow At A Cagr Of 36.3% From 2018 &Ndash; 2026 And Is Expected To Reach Us$ 10.8 Billion By 2026 As Per Coherent Market Insights.Pankaj R Patel, Chairman, Zydus Group Said, &Ldquo;We Are Pleased That The Us Fda Has Granted An Orphan Drug Designation Apart From The Earlier Fast Track Designation To Saroglitazar Mg For The Treatment Of Primary Biliary Cholangitis. This Underlines The Urgent Need To Address This Serious Health Condition Which Is An Unmet Medical Need. We Are Committed In Our Clinical Development Efforts To Improve The Quality Of Life Of Patients Suffering From Pbc With A Safe And Efficacious Treatment.&Rdquo;
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!